Eli Lilly and Company (LLY)
Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win
Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk acquisitions in infectious diseases and other areas. LLY's infectious disease deals offer long-term upside, notably with amezosvatein showing superior tolerability to Shingrix, but meaningful revenues are unlikely before 2030. Retatrutide's phase 3 results raise the efficacy bar for obesity drugs, though tolerability issues may limit its uptake versus the better tolerated tirzepatide.
Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
Healthy Returns: Eli Lilly makes a new push into vaccines – here's what to know
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease prevention. The deals mark a strategic push for Lilly into vaccine development, an area the company said aligns with its broader goal of addressing major global health challenges beyond its core diabetes and obesity portfolio, which has been a key driver of recent cash flow.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly's effort to expand into infectious disease research and development. Shares edged higher in premarket trading on the news.
Lilly Agrees to Buys Trio of Vaccine Developers
The weight-loss drug market leader is renewing a focus on infectious-disease prevention.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case
Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company.
